Latest Period
Q4 2025
Security Snapshot
Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") Institutional Ownership
CUSIP: 002942100
13F Institutional Holders and Ownership History for Q4 2025
Institutions Reporting
1
Shares (Excl. Options)
1,289,263
Price
$13.12
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.00001 per share (the "Shares")
- Shares outstanding
- 21,303,054
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,289,263
- Total reported value
- $16,921,577
- % of total 13F portfolios
- 0%
- Share change
- -70,620
- Value change
- -$926,888
- Number of holders
- 1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") is tracked under CUSIP 002942100.
- 1 institution reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Latest quarter on this page is Q4 2025.
- Additional quarter-over-quarter change detail appears as history expands.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 1 institution filings for Q4 2025.
Investment Quick Answers
What is CUSIP 002942100?
CUSIP 002942100 identifies 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 002942100:
Significant Owners of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 5.6% | 1,192,971 | Kenneth Griffin | 14 Feb 2025 |
As of 31 Dec 2025, 1 institutional investors reported holding 1,289,263 shares of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares"). This represents 6.1% of the company’s total 21,303,054 outstanding shares.
Institutional Holders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,289,263 | $16,921,577 | -$926,888 | $13.12 | 1 |